ZYUS Life Sciences

Business news, market intelligence, and global industry analysis.

The Latest

Representative image of a quantum computing lab setup showing superconducting and neutral atom research systems, illustrating Google’s two-qubit strategy and what its neutral atom expansion could mean for IonQ, QuEra, and the future of quantum computing.

Google’s two-qubit strategy: What the neutral atom expansion means for IonQ, QuEra, and the future of quantum computing

Representative image of enterprise agentic AI workflows as Oracle Corporation expands AI Agent Studio for Fusion Applications, highlighting how enterprise automation, workflow orchestration, and AI agents are reshaping business software.

Can Oracle (NYSE: ORCL) turn enterprise AI from demo theater into operational software that actually runs the business?

Dev Accelerator (NSE: DEVX) raises up to Rs 35cr to lock in 4.5 lakh sq ft Ahmedabad campus

Pepper Money (ASX: PPM) rejects Challenger’s revised A$2.25 bid, ending takeover talks

Is a C$16m LIFE offering from ZYUS Life Sciences the catalyst investors are watching in cannabinoid pharma?

ZYUS Life Sciences launches a C$15–16 million LIFE offering to accelerate clinical execution and regulatory readiness. Find out what it means for investors.

μFR system
αvβ6-integrin
α4β7 integrin
ZYUS Life Sciences
Zyrtec
Zyprexa Zydis
Zynga
Zynext Ventures USA LLC
Zynext Ventures
Zynex

January 15, 2026